Hsbc Holdings PLC reduced its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) by 18.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 18,913 shares of the biopharmaceutical company’s stock after selling 4,371 shares during the quarter. Hsbc Holdings PLC’s holdings in Puma Biotechnology were worth $45,000 at the end of the most recent quarter.
Other institutional investors also recently bought and sold shares of the company. Gladius Capital Management LP purchased a new stake in Puma Biotechnology in the 2nd quarter worth $28,000. Jane Street Group LLC purchased a new stake in shares of Puma Biotechnology in the second quarter valued at $32,000. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Puma Biotechnology in the third quarter valued at $35,000. Mackenzie Financial Corp bought a new position in shares of Puma Biotechnology during the first quarter valued at approximately $35,000. Finally, Mirabella Financial Services LLP bought a new position in shares of Puma Biotechnology during the first quarter valued at approximately $73,000. 60.58% of the stock is owned by institutional investors.
Analyst Ratings Changes
PBYI has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Puma Biotechnology in a research note on Monday, March 6th. StockNews.com lowered Puma Biotechnology from a “buy” rating to a “hold” rating in a research report on Tuesday, February 28th.
Puma Biotechnology Stock Down 4.4 %
In other news, CEO Alan H. Auerbach sold 27,241 shares of the firm’s stock in a transaction that occurred on Tuesday, January 3rd. The stock was sold at an average price of $4.18, for a total value of $113,867.38. Following the transaction, the chief executive officer now owns 6,852,638 shares in the company, valued at $28,644,026.84. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Alan H. Auerbach sold 27,241 shares of the stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $4.18, for a total transaction of $113,867.38. Following the completion of the transaction, the chief executive officer now directly owns 6,852,638 shares in the company, valued at approximately $28,644,026.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Maximo F. Nougues sold 10,499 shares of the business’s stock in a transaction dated Tuesday, January 3rd. The shares were sold at an average price of $4.18, for a total transaction of $43,885.82. Following the completion of the sale, the chief financial officer now owns 100,427 shares in the company, valued at $419,784.86. The disclosure for this sale can be found here. Insiders have sold a total of 41,200 shares of company stock worth $172,216 over the last quarter. 21.20% of the stock is currently owned by corporate insiders.
About Puma Biotechnology
Puma Biotechnology, Inc is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use.
- Get a free copy of the StockNews.com research report on Puma Biotechnology (PBYI)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.